SBIR-STTR Award

Method for Increasing Gene Therapy Efficacy and Safety
Award last edited on: 12/9/02

Sponsored Program
SBIR
Awarding Agency
NIH : NCI
Total Award Amount
$100,000
Award Phase
1
Solicitation Topic Code
-----

Principal Investigator
Julian D Down

Company Information

Biotransplant Inc

196 Boston Avenue Suite 2800
Medford, MA 02155
   (781) 393-8500
   rick.capasso@biotransplant.com
   www.biotransplant.com
Location: Single
Congr. District: 05
County: Middlesex

Phase I

Contract Number: 1R43CA090097-01A1
Start Date: 00/00/00    Completed: 00/00/00
Phase I year
2002
Phase I Amount
$100,000
The aim of this proposal is to develop a non-myeloablative conditioning protocol with increased safety and efficacy for the induction of specific immune tolerance to genetically modified cells. Potential applications of gene therapy in the treatment of genetic and autoimmune disorders are widespread, but progress has suffered from a severe reduction in efficacy due to immune reactions raised against therapeutic transgene products. Induction of specific immune tolerance through mixed hematopoietic chimerism is an established methodology that can effectively re-educate the immune system to eliminate immune rejection. To achieve engraftment of allogeneic stem cells, conditioning requirements are associated with toxicities, and graft-versus-host disease is a common side effect. Studies have shown that molecular chimerism can be used to induce tolerance. Our preliminary data suggest that specific immune tolerance can be induced to a single immunogenic protein expressed on autologous cells, and that conditioning requirements for transplantation of molecularly modified autologous cells are less than those required for allogeneic transplants. We believe that the effectiveness of gene therapy can be greatly improved by inducing specific immune tolerance to foreign proteins to be transferred and that this can be accomplished using non-toxic protocols.

Thesaurus Terms:
evaluation /testing, gene therapy, immune tolerance /unresponsiveness, technology /technique development autologous transplantation, diagnosis procedure safety, green fluorescent protein biotechnology, laboratory mouse

Phase II

Contract Number: ----------
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
----
Phase II Amount
----